The Medicare program could be paying multiple times for prescription drugs for hospice beneficiaries, a new federal report suggests.
Read the full story: http://tinyurl.com/6v4bews
Source: ModernHealthcare.com
HHS' inspector general's office conducted a nationwide review of prescription drugs for hospice beneficiaries between January and December 2009 and found that Medicare Part D paid for a variety of prescription medications—including analgesic, anti-nausea, laxative and anti-anxiety drugs and drugs to treat chronic obstructive pulmonary disease—that should have been covered under the per diem payments made to hospice organizations under Medicare Part A. Investigators found 198,543 hospice beneficiaries who, through the Medicare Part D program, received 677,022 prescription drugs that potentially should have been covered under the daily payments made to hospice organizations. Meanwhile, Part D paid pharmacies more than $33.6 million for these drugs, and beneficiaries paid more than $3.8 million in copayments.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen